30 results about "Premalignant Cell" patented technology

The invention discloses a dynamic identification method for unusual cells before young tumors based on multi-omics data, and relates to the technical field of cell unusual identification. A dynamic correlation intensity matrix and a cumulative effect contribution matrix are constructed, a differentiation screening strategy is implemented according to individual response characteristics, and the unusual cells before young tumors are identified. And the abnormal dynamic high-fidelity identification of the young tumor pre-cells is realized. And aiming at individuals of different response types, an instant path, a long-term path or a double-path fusion strategy is respectively adopted, key behavior data is accurately screened, and the input quality is improved. According to the method, redundant interference is effectively eliminated, the simulation capability of the model on key processes such as immunosuppression and DNA damage accumulation is enhanced, the biological rationality and prediction precision of a cell state evolution sequence are remarkably improved, and the problems of model response lag, low calculation efficiency and output distortion caused by data noise in the prior art are solved; and a reliable technical support is provided for early warning and individualized intervention of precancerous lesions.

The invention discloses a drug perturbation diffusion prediction method fused with cell description, and relates to the technical field of drug perturbation prediction.The method comprises the steps that firstly, a cell perturbation transcriptome database is preprocessed, and a cell-drug combination containing drug characteristics, cell line gene expression and cell line description characteristics is obtained to serve as training data; and then constructing a drug disturbance prediction diffusion model based on cell description, training the drug disturbance prediction diffusion model by using the training data, and finally inputting Gaussian white noise, cell line gene expression before disturbance, drug characteristics and cell line description characteristics into the trained model to predict cell line gene expression after drug disturbance. According to the method, cell line description characteristics are introduced, so that the perception capability of the model on intercellular biological differences is enhanced, and the generalization performance of cross-drug and cross-cell lines is improved.

The utility model relates to the technical field of cell culture, and discloses a cell culture bottle, comprising a culture bottle, wherein a bottom wall is arranged at the bottom of the culture bottle, a liquid-blocking and breathable membrane is arranged at the opening of the culture bottle, a closing cover is installed on the outside of the culture bottle, a fixing ring is fixedly connected to the outside of the culture bottle, a plug is arranged inside the fixing ring, and a sealing block is fixedly connected to the inside of the plug. The cell culture bottle has the advantages of being convenient for adding culture fluid and reducing the influence of the external environment on the internal environment of the culture bottle. The plug is used to close a pipeline, and the culture bottle is divided into two cavities by a partition plate, so that culture fluid can be added through the pipeline, and a blocking mechanism is opened by gravity to add culture fluid to the inside of the cavity for culturing cells, so as to complete the addition of culture fluid, thereby solving the problem that the external environment may contaminate cells when the closing cover is opened to pour the culture fluid through the opening during the current cell culture process.

The invention provides application of an Aars1 gene in regulation and control of expression of an exogenous recombinant protein, and belongs to the technical fields of recombinant protein expression, gene engineering and cell culture. According to the CHO cell line, shRNA fragments of targeted Aars1 genes are inserted and integrated into piggyBac transposon vectors, a recombinant vector for inhibiting / silencing the Aars1 genes and an Aars1 low-expression CHO cell line are constructed, the CHO cell line can remarkably reduce the mRNA expression level of the Aars1, meanwhile, the CHO cell line serves as a host cell for recombinant protein expression, and compared with a wild type CHO cell line, the CHO cell line has the advantages that the expression level of the CHO cell line is greatly improved; the recombinant adalimumab can improve the expression quantity of recombinant protein (the expression quantity of the recombinant adalimumab is increased by 3.1 + / -0.18 times), effectively overcomes the problem of low expression level of the existing CHO cell expression system, and can be used for further constructing a recombinant protein expression system or kit.

The subject matter of this specification can be implemented in, among other things, methods, systems, computer-readable storage medium. A method can include receiving cell growth data with a current cell culture of a cell growth system. The cell growth data includes growth input parameter values indicative of a growth rate of the current cell culture. The method can further include identifying, using a first machine learning model, a prescriptive action to alter a yield of a target product of the current cell culture based on the cell growth data. The prescriptive action modifies a metabolism rate of the current cell culture. The method further includes performing at least one of displaying the identified prescriptive on a graphical user interface (GUI) and / or causing the cell growth system to perform the identified prescriptive action.

The present disclosure is directed to method of generating human glomeruli endothelial cells (HGECs) from human endothelial cells (ECs), comprising expressing in human ECs an exogenous nucleic acid encoding a T-box transcription factor 3 (Tbx3), alone or in combination with one or more of PR domain zinc finger protein 1 (Prdm1), GATA Binding Protein 5 (Gata5) and Pre-B-Cell Leukemia Transcription Factor 1 (Pbx1). Disclosed also are HGECs produced by the methods of the instant disclosure, as well as methods for using the same.

The application discloses a kind of young tumor pre-cell abnormal dynamic identification method based on multi-omics data, it is related to cell abnormality identification technical field, the application is by constructing dynamic correlation strength matrix and cumulative effect contribution matrix, according to individual response characteristics Implementation of differentiating screening strategy, realize the high fidelity identification of young tumor pre-cell abnormal dynamics.For different response type individuals, respectively using instant path, long-term path or double-path fusion strategy, accurately screening key behavior data, improve input quality.The method effectively eliminates redundant interference, enhances the model's ability to simulate key processes such as immune suppression and DNA damage accumulation, significantly improves the biological rationality and prediction accuracy of cell state evolution sequence, solves the model response lag, low computational efficiency and output distortion problems caused by data noise in the prior art, and provides reliable technical support for early warning and individualized intervention of pre-tumor lesions.

The invention discloses a high-bionic in-vivo immune microenvironment in-vitro skin model and application, and belongs to the technical field of biological medicine. The preparation method of the in-vitro skin model of the high-bionic in-vivo immune microenvironment comprises the following steps: firstly, adding a culture medium into the lower layer of a six-pore plate, then adding a mouse bone marrow cell suspension, then putting the six-pore plate into a Transwell chamber, flatly laying separated mouse skin on an absorptive gelatin sponge, putting the absorptive gelatin sponge into the Transwell chamber, adding the culture medium into the Transwell chamber, and then putting the mouse skin into the transwell chamber to obtain the in-vitro skin model of the high-bionic in-vivo immune microenvironment. Placing the six-hole plate in a cell incubator for culturing to obtain the in-vitro skin model. According to the in-vitro skin-bone marrow cell co-culture system, an immune environment is provided for the in-vitro skin by introducing bone marrow cells, so that the culture environment of the in-vitro skin is more complete, the difficulties that cell components are simple and the immune environment is deficient at present can be solved, and the in-vitro skin-bone marrow cell co-culture system is more in line with the 3R principle and is high in bionic property and low in cost.

The invention belongs to the technical field of nano medicine, and particularly discloses a method for obtaining exosomes with different cell biological functions, which comprises the following steps: preparing hybrid cells HCs integrating different cell functions by a cell fusion method, and further collecting exosomes H / Exos derived from the hybrid cells. The invention also discloses the exosome and application of the exosome in preparation of drugs. Different hybrid cells have multiple functions of cells before fusion, and exosomes secreted by the hybrid cells inherit the functions of the hybrid cells. The hybrid cells can continuously secrete exosomes with the characteristics of the two parent cells in the proliferation process. The defect that the end-to-end differentiated cells cannot be proliferated is overcome, so that large-scale preparation of the natural multifunctional exosome can be realized, and a new method is provided for customized exosome preparation for disease treatment.

The present invention relates to a novel and efficient method for the large-scale selective generation of γδ T cells, preferably human V51+ γδ T cells, optimal for clinical application in adoptive immunotherapy against cancer. In this regard, taking into account that both human cord blood HPCs and human early thymic progenitor cells, the current source of stem cells of choice in the clinic, can efficiently generate de novo human γδ T cells in response to Notch signaling, most efficiently in response to the Notch ligand Jag2, the method comprises inducing the differentiation of cord blood CD34+ hematopoietic progenitor cells (HPCs) and / or human CD34+ early thymic progenitor cells by activating these progenitors with the Jag2 Notch ligand.

Disclosed herein are compositions and methods for treating inflammatory diseases, comprising inhibiting or blocking the interaction between apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC) and pro-cytokines.

Methods for treating leukemia are disclosed based on detecting specific cell states and transcriptional programs within leukemic cells. This disclosure presents a novel therapeutic method for treating acute lymphoblastic leukemia (ALL), including BCR-ABL positive and BCR-ABL1-like ALL subtypes. The method involves detecting specific cell states and transcriptional programs in patient samples and administering targeted therapies based on these characteristics. For a pre-B cell-like state or pre-BCR signaling program, a combination of tyrosine kinase inhibitor (TKI) and SYK inhibitor is used. Conversely, a progenitor-like state or stress-autophagy program is treated with a TKI and a p38 MAPK inhibitor. This approach aims to improve treatment efficacy by tailoring therapy to the leukemia's unique molecular and cellular features, particularly in relapsed cases or when minimal residual disease is present.

The present invention relates to an antibody, or an antigen binding fragment thereof, and to the CAR T-cell comprising the antigen binding fragment of said antibody. The invention also discloses to the polynucleotides encoding said antibody, the vector, the cells, the antibody-drug conjugate, and the composition comprising the antibody, the antigen binding fragment thereof, and / or to the CAR T-cell, all of them being useful in the treatment and / or prevention of leukemia, more preferably T-cell acute lymphoblastic leukemia (T-ALL), still more preferably T-ALL pre-TCR+, in a subject.

The invention belongs to the technical field of gene engineering, and particularly relates to application of a TP63 gene in improving the expression quantity of exogenous recombinant protein, and the nucleotide sequence of the TP63 gene is shown as SEQ ID NO.1. According to the invention, the TP63 overexpression vector is creatively applied to construction of a recombinant protein expression system, the TP63 overexpression vector is transfected into CHO cells to construct a CHO cell line for overexpressing TP63, and the CHO cell line can significantly improve the expression level of TP63 protein. Meanwhile, the CHO cell line is used as a host cell for recombinant protein expression, compared with a wild type CHO cell line, the expression quantity of recombinant protein can be increased, and the problem that the expression level of antibody expression quantity in an existing CHO cell expression system is low is effectively solved.

The present invention discloses a cell storage and transplantation device for small animals under the renal capsule, and relates to the field of experimental instruments for islet transplantation. The cell storage and transplantation device for small animals under the renal capsule includes two major parts: a storage tube and a storage box. The storage tube includes an outer tube and an inner tube. The inner side of the storage box ice box is provided with six placement slots. The device provided by the present invention can directly store cell suspensions. The storage tube can be directly placed in a low-speed centrifuge for centrifugation. The cells will settle to the lower section of the inner tube of the storage tube. The storage tube with centrifuged cells can be directly placed in a matching storage box for storage and transportation. The cells do not need to be transferred before cell transplantation, and the cell viability is greatly improved. The inner tube of the storage tube is compatible with the size of a 10μL pipette, and the transplantation can be directly performed with a 10μL pipette. When injecting, the round closed end of the gel at the end of the lower section of the inner tube of the storage tube is peeled off, and the cell transplantation can be performed directly.

Provided are activatable proprotein homodimers comprising two separate but identical polypeptide chains, each chain comprising a fragment antigen-binding (Fab) region that specifically binds to human PD-1 or human PD-L1 or human B7H3, a hinge / Fc domain, a linker, an IL-2 protein, a protease cleavable linker, and an IL-2Rα protein. Also provided are related pharmaceutical compositions and methods of use thereof.

The utility model provides a cell culture bottle placing rack, belongs to the technical field of placing racks, and effectively solves the problems of poor fixing effect and low applicability of the existing cell culture bottle rack. According to the technical scheme, the device comprises a horizontally-arranged bottom plate, the bottom of the rear side of the bottom plate is fixedly connected with a vertical plate, the vertical plate is provided with a height adjusting component, the height adjusting component is connected with a thickness adjusting component, the thickness adjusting component is connected with a width adjusting component, the bottom plate is provided with a bottom limiting component, and the bottom limiting component is connected with a traction component. The cell culture bottle placing rack has the beneficial effects that the cell culture bottle placing rack is convenient to use, can be adjusted in a multidirectional and three-dimensional manner and is suitable for cell culture bottles with different specifications.

The present invention provides activatable preprotein homodimers comprising two separate but identical polypeptide chains, each chain comprising a fragment antigen binding (Fab) region that specifically binds to human PD-1 or human PD-L1 or human B7H3, a hinge / Fc domain, a linker, an IL-15 protein, a protease cleavable linker, and an IL-15R [alpha] protein. Related pharmaceutical compositions and methods of use thereof are also provided.

The invention discloses a method for improving the expression quantity of transient transfected recombinant protein of CHO-K1 cells. The method comprises the following steps: S1, recovering the CHO-K1 cells and subculturing the CHO-K1 cells; s2, adding the cells of which the density is adjusted into a recombinant protein DNA-PEI compound to carry out transient transfection; s3, adding an additive into the transfection system, wherein the additive is a mixture of a sodium butyrate solution and an EN3 solution. According to the method, the culture medium, the cell density before transfection and the proportion of recombinant protein DNA to PEI in a transfection system are optimized, and the additive is added after transfection, so that the antibody expression after cell transfection is promoted, and the expression level of the recombinant protein is effectively improved.

Provided herein are populations of IL2 dependent cells that express high affinity CD16 but do not express IL-2. The cells maintain stable expression of the Fc receptor CD16 while maintaining cytotoxicity. In some embodiments, the expression level of CD16 when the cell is activated is reduced by no more than 20% compared to the expression level of CD16 on the cell prior to activation. Also provided are compositions and kits comprising the cells, as well as methods of making and using IL2 dependent cells.

The invention relates to the technical field of recombinant protein expression and cell culture, in particular to a Tcf7l1 overexpression vector, a cell line, a system, a kit, a construction method and application. The Tcf7l1 transcription factor is creatively selected as a genetic engineering modification target of recombinant protein expression, for example, a Tcf7l1 overexpression vector is transfected to a CHO cell, stable overexpression of CHO cell Tcf7l1 is achieved, the overexpressed Tcf7l1 transcription factor regulates the growth performance of the CHO cell, and when the Tcf7l1 transcription factor serves as a host cell for recombinant protein expression, the yield of recombinant protein is increased; compared with a wild type CHO cell line, the Tcf7l1 overexpression cell line constructed by the invention is used as a foreign protein recombinant expression system, so that the recombinant protein expression quantity is increased, and the problem of low expression level of the existing CHO cell expression system is effectively solved.

Provided herein are activatable proprotein homodimers comprising two separate but identical polypeptide chains, each chain comprising a fragment antigen binding (Fab) region that specifically binds to human PD-1 or human PD-L1 or human B7H3, a hinge / Fc domain, a linker, an IL-2 protein, a protease cleavable linker, and an IL-2R [alpha] protein. Related pharmaceutical compositions and methods of use thereof are also provided.

Nanostraws and to methods of utilizing them in order to deliver biologically relevant molecules such as DNA, RNA, proteins etc., into non-adherent cells such as immune cells, embryos, plant cells, bac- teria, yeast etc. The methods described herein are repeatedly capable of delivering biologically relevant cargo into non-adherent cells, with high cell viability, dosage control, unaffected proliferation or cellular devel- opment, and with high efficiency. Among other uses, these new delivery methods will allow to scale pre-clinical cell reprogramming techniques to clinical applications.

An apparatus and method for controllably moving a containment vessel for mammalian gestation, including to provide continuous intermittent motion and culture of an embryo in the containment vessel. The method includes determining compatibility or biocompatibility of a material or substance for gestational development of an embryo. The apparatus includes a motion system having one or more fasteners configured to attach to the containment vessel, a platform configured to support the motion system and allow the containment vessel to move with respect at least one axis while being imaged by an image pickup device, and a drive system having a controller configured to adjust movement of the containment vessel with respect to the at least one axis, including at least one of an inversion frequency, a direction of rotation, a velocity, a rate of change in the inversion frequency, a rate of change in the direction of rotation, and a rate of change in the velocity of the containment vessel, for mammalian gestation.

The utility model relates to the technical field of biological experiment equipment, in particular to a cell culture device. The culture plate or the culture cup is provided with a gas-liquid interaction channel, the gas-liquid interaction channel is communicated with the culture hole, and the culture hole is communicated with the liquid storage tank through the gas-liquid interaction channel, so that the culture medium in the liquid storage tank can enter the culture hole through the gas-liquid interaction channel. Due to the fact that the culture plate or the culture cup is detachably arranged on the liquid storage plate, when a culture medium needs to be replaced, the culture plate or the culture cup can be separated from the liquid storage plate, then the culture medium in the liquid storage groove of the liquid storage plate is poured out, rapid replacement of the culture medium is achieved, and the problem that an existing cell culture plate is long in liquid replacement time is solved. Due to the fact that the culture medium can automatically flow out of the gas-liquid interaction channel, the culture medium can be replaced more thoroughly, the residual quantity of the culture medium in different culture holes is consistent, the culture medium does not need to be sucked by a suction pipe, organoid damage is not prone to being caused, and the differentiation efficiency can be improved.

The invention provides an ATG13 gene and application of the ATG13 gene in improvement of exogenous recombinant protein expression, and belongs to the technical field of gene engineering. The nucleotide sequence of the ATG13 gene provided by the invention is as follows: (1) a nucleotide sequence as shown in SEQ ID NO.2; or (2) a nucleotide sequence which is obtained by substituting and / or deleting and / or adding one or more nucleotides to the nucleotide sequence as shown in SEQ ID NO.2 and expresses the same functional protein. Furthermore, through overexpression of the ATG13 gene in the CHO cell, the expression quantity of the exogenous recombinant protein can be remarkably improved, the problem that the expression level of an existing CHO cell expression system is low is effectively solved, and a direction is provided for construction of the CHO cell and production of the recombinant protein.

The invention provides a recombinant vector for overexpressing a Tgm2 gene, a recombinant CHO cell and application of the recombinant vector and the recombinant CHO cell in improvement of exogenous recombinant protein expression, and belongs to the technical field of genetic engineering. The gene Tgm2 for coding transglutaminase 2 has the effect of improving the expression level of exogenous recombinant protein in mammalian cells creatively; an overexpression vector of the gene Tgm2 is transfected to CHO cells to construct the CHO cell line for overexpressing the Tgm2, the CHO cell line can remarkably improve the mRNA and protein expression level of the Tgm2, meanwhile, the CHO cell line serves as a host cell for recombinant protein expression, compared with a wild type CHO cell line, the expression quantity of recombinant protein can be increased, and the expression level of the recombinant protein can be increased. The problem that the expression level of an existing CHO cell expression system is low is effectively solved.

An apparatus and method for controllably moving a containment vessel for mammalian gestation, including to provide continuous intermittent motion and culture of an embryo in the containment vessel. The method includes determining compatibility or biocompatibility of a material or substance for gestational development of an embryo. The apparatus includes a motion system having one or more fasteners configured to attach to the containment vessel, a platform configured to support the motion system and allow the containment vessel to move with respect at least one axis while being imaged by an image pickup device, and a drive system having a controller configured to adjust movement of the containment vessel with respect to the at least one axis, including at least one of an inversion frequency, a direction of rotation, a velocity, a rate of change in the inversion frequency, a rate of change in the direction of rotation, and a rate of change in the velocity of the containment vessel, for mammalian gestation.

Described herein are methods of using fusion proteins consisting of elements such as one or more proteins / polypeptides capable of translocation into the endoplasmic reticulum (ER) and fragments or variants of interleukin 18 (IL-18) or IL-18. Proteins / polypeptides capable of translocation into the ER include, but are not limited to, immunoglobulins such as Fc regions, VHH antibodies and scFvs, and globular proteins such as serum albumin. IL-18 can be a precursor IL-18 similar to a native procytokine, wherein IL-18 is fused to the C-terminus of its propeptide or propeptide variant. These fusion proteins are useful in methods of treating cancer or fibrosis by activating IL-18 receptor complex (RC) signaling on a cell, releasing or exposing mature IL-18 in or adjacent to a tumor, and / or increasing memory CD8-T cell proliferation.

The invention relates to the technical field of gene engineering. The invention provides an application of an SFN gene in improvement of CHO cell recombinant protein expression stability. A nucleotide sequence of the SFN gene is shown as SEQ ID NO.1. The invention further provides an application of the SFN gene in improvement of CHO cell recombinant protein expression stability. The SFN overexpression vector is constructed and transfected to the recombinant CHO cell, the recombinant CHO cell overexpressing the SFN is obtained through screening, cell passage is carried out, in the long-term culture process of the recombinant CHO cell overexpressing the SFN, the expression attenuation of the recombinant antibody can be obviously slowed down, the expression stability of the recombinant antibody is improved, and the recombinant CHO cell overexpressing the SFN is obtained. The problem of recombinant protein expression attenuation caused by cell passage at present is effectively solved.